Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models-Reference-Cited by-同舟云学术

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

Published:2019-03-23 Issue:5 Volume:145 Page:1382-1394
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Sugawara Tatsuo¹,Baumgart Simon J.¹,Nevedomskaya Ekaterina¹,Reichert Kristin¹,Steuber Holger²,Lejeune Pascale¹,Mumberg Dominik¹,Haendler Bernard¹^ORCID

Affiliation:

1. Oncology II, Preclinical Research, Research and Development, PharmaceuticalsBayer AG Berlin Germany

2. Structural Biology, Lead Discovery Berlin, Small Molecule Innovation, Research and Development, PharmaceuticalsBayer AG Berlin Germany

Funder

Bayer AG

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32242

Reference50 articles.

1. Global cancer statistics, 2012

2. Drug discovery in advanced prostate cancer: translating biology into therapy

3. Recent Advances in Prostate Cancer Treatment and Drug Discovery

4. Integrative Clinical Genomics of Advanced Prostate Cancer

5. The long tail of oncogenic drivers in prostate cancer

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer;Advanced Science;2024-07-03

2. Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer;Bioorganic Chemistry;2024-07

3. New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact;Expert Opinion on Drug Metabolism & Toxicology;2024-05-22

4. An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021);Anti-Cancer Agents in Medicinal Chemistry;2024-05

5. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis;Molecular Oncology;2024-01-15